Navigation Links
SyntheMed Receives Australian Regulatory Approval for REPEL-CV(R)
Date:5/28/2009

eared from the body.

About SyntheMed, Inc.

SyntheMed, Inc. is a biomaterials company engaged in the development and commercialization of anti-adhesion products. The company is primarily focused on the advancement and expansion of product development programs based on its proprietary bioresorbable polymer technology.

Statements in this Press Release that are not statements of historical fact, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such risks and uncertainties include but are not limited to (i) potential adverse developments regarding the company's efforts to obtain and maintain FDA and other required regulatory approvals; (ii) potential inability to secure funding as and when needed to support the company's future activities and (iii) unanticipated delays associated with manufacturing and marketing activities. Reference is made to the company's Annual Report on Form 10-KSB for the year ended December 31, 2008 for a description of these, as well as other, risks and uncertainties.


'/>"/>
SOURCE SyntheMed, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. FDA Approves SyntheMeds REPEL-CV(R) Adhesion Barrier for Use in Pediatric Cardiac Surgery
2. SyntheMed Announces FDA Clearance of SinusShield(TM)
3. SyntheMed Announces New Management Appointments
4. SyntheMed Completes $4.0 Million Equity Placement
5. SyntheMed To Present at the AdvaMed 2008 MedTech Conference
6. SyntheMed to Present at Canaccord Adams Small-Cap Orthopedics Conference
7. SyntheMed Files Universal Shelf Registration
8. SyntheMed to Present at the Acumen BioFin Conference
9. SyntheMed to Host Symposium on Adhesions in Cardiac Surgery
10. Astellas Receives FDA Approval for Use of Prograf(R) (Tacrolimus) in Conjunction With Mycophenolate Mofetil (MMF) in Kidney Transplant Recipients
11. Sanofi Pasteur Receives Seed Virus to Produce New Influenza A(H1N1) Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... August 27, 2014 Varian Medical Systems ... its current Salt Lake City manufacturing facility and allow ... Utah to ultimately create 1,000 new full time jobs ... , “Utah is home to hardworking people with immense ... credited with Varian’s success in the manufacturing of our ...
(Date:8/27/2014)... Green & Grow Inc. (GGI) has ... and secured Otter Capital as a significant new partner. ... of GGI’s Agriplier™ technology, building on recent compelling field ... our first meeting, we have been impressed with Otter ... said Alan Sobba, President and CEO of GGI. “We ...
(Date:8/27/2014)... -- Rhythm, a biopharmaceutical company developing peptide therapeutics that ... metabolic disorders, announced today that it has filed a ... and Exchange Commission (SEC) relating to the proposed initial ... number of shares to be offered and the price ... Citigroup and Cowen and Company will act ...
(Date:8/27/2014)... Livermore, California (PRWEB) August 27, 2014 ... (LLNL), through Lawrence Livermore National Security ... million to develop and deliver a state-of-the-art laser ... Beamlines facility (ELI Beamlines), under construction in the ... design performance, the laser system, called the " ...
Breaking Biology Technology:Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 2Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 3Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3Rhythm Files Registration Statement for Proposed Initial Public Offering 2LLNL Synchs up with ELI Beamlines on Timing System 2LLNL Synchs up with ELI Beamlines on Timing System 3
... repairing damaged human tissue doesn,t wrinkle up when it ... of California, San Diego marks a significant breakthrough in ... of native human tissue. Shaochen Chen, professor ... Diego Jacobs School of Engineering, hopes future tissue patches, ...
... Mass., May 26, 2011 New England Biolabs (NEB), ... reagents for the life science industry, extends its global ... France, located at Bioparc Genopole in Evry, just south ... Ellard, President and CEO of NEB Inc., was on ...
... 2011 Addressing the issue of data overload from next-generation ... ) today launched its LifeScope™ 2.0 Genomic Analysis Software ... genomic sequencing instruments to study human disease such as cancer. ... A single next generation sequencing instrument can generate nearly 200 ...
Cached Biology Technology:Nanoengineers invent new biomaterial that more closely mimics human tissue 2New England Biolabs Opens New Subsidiary Office in France 2Life Technologies Simplifies, Organizes and Speeds Analysis of Genomic Data Through Launch of New LifeScope Bioinformatics Software 2Life Technologies Simplifies, Organizes and Speeds Analysis of Genomic Data Through Launch of New LifeScope Bioinformatics Software 3Life Technologies Simplifies, Organizes and Speeds Analysis of Genomic Data Through Launch of New LifeScope Bioinformatics Software 4Life Technologies Simplifies, Organizes and Speeds Analysis of Genomic Data Through Launch of New LifeScope Bioinformatics Software 5
(Date:8/27/2014)... The mechanical force that a single fungal cell or bacterial ... but it plays a heavy role in setting up some ... it may not be too much of a stretch to ... the ability to respond to the touch of beneficial fungi, ... professor of agronomy at the University of Wisconsin-Madison. , ...
(Date:8/27/2014)... Aug. 27, 2014  WaferGen Bio-systems, Inc. (NASDAQ: WGBS) ... underwritten public offering of units of common stock and ... gross proceeds of $20 million, prior to deducting underwriting ... Company.  The shares and warrants are immediately separable and ... sold in the offering consists of 2,000 shares of ...
(Date:8/27/2014)... of North America,s megafauna mastodons, short-faced bears, giant ... disappeared close to 13,000 years ago at the ... massive extinction has long been debated by scientists who, ... A group of scientists, including UC Santa Barbara,s James ... posited that a comet collision with Earth played a ...
Breaking Biology News(10 mins):A touching story: The ancient conversation between plants, fungi and bacteria 2A touching story: The ancient conversation between plants, fungi and bacteria 3WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 2WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 3Nanodiamonds are forever 2Nanodiamonds are forever 3
... expect to live slightly longer than Europeans. This has since ... now live about a year-and-a-half less, on average, than their ... other developed nations. How did Americans fall behind? A ... & Medicine is the first to calculate the fiscal ...
... shows the prevalence of gout in the U.S. has risen ... (4%) Americans. Prevalence of increased uric acid levels (hyperuricemia) also ... frequency of obesity and hypertension may be associated with the ... in Arthritis & Rheumatism , a journal published by ...
... east coast of Canada are showing signs of recovery more ... 1990s, according to research published today in Nature . ... an ecosystem that was pushed out of balance and that ... professor in the Department of Biology, former principal at Queen,s, ...
Cached Biology News:Getting 50-year-old Americans as healthy as Europeans could save Medicare and Medicaid $632 billion by 2050 2Gout prevalence swells in US over last 2 decades 2Cod resurgence in Canadian waters 2
This STAT antibody sampler pack contains 8 monoclonal ,STAT antibodies....
Kanamycin is used for selection of resistant bacteria. C18H36N4O11xH2SO4. Contains 10 mg/ml kanamycin (base) utilizing kanamycin sulfate in 0.85% saline....
...
...
Biology Products: